First-line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes.
Advanced stage Hodgkin's lymphoma
clinical outcome
frontline chemotherapy
interim PET scans
safety
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
13
12
2021
revised:
14
03
2022
accepted:
17
03
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
Classical Hodgkin lymphoma (cHL) is curable in 90% of cases, but advanced stage patients who do not respond well to first-line (1L) therapy have poorer outcomes. This retrospective study examines patient characteristics, treatment patterns, clinical outcomes, and safety management of 1L cHL therapies in common clinical practice in Italy (IT), Israel (IL), and Spain (SP). The overall sample (
Identifiants
pubmed: 35846037
doi: 10.1002/jha2.426
pii: JHA2426
pmc: PMC9176002
doi:
Types de publication
Journal Article
Langues
eng
Pagination
415-425Informations de copyright
© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Références
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29
pubmed: 29796651
Br J Haematol. 2017 Jan;176(1):65-75
pubmed: 27766636
Ann Hematol. 2018 Aug;97(8):1301-1315
pubmed: 29802458
Ann Oncol. 2014 Aug;25(8):1622-8
pubmed: 24827123
Cancer Manag Res. 2018 Nov 22;10:6017-6028
pubmed: 30538551
J Glob Oncol. 2019 Nov;5:1-13
pubmed: 31834832
Leuk Lymphoma. 2019 Apr;60(4):927-933
pubmed: 30277120
Lancet. 2018 Dec 23;390(10114):2790-2802
pubmed: 29061295
Am Soc Clin Oncol Educ Book. 2016;35:e376-85
pubmed: 27249744
J Clin Oncol. 1998 Dec;16(12):3810-21
pubmed: 9850026
Am J Hematol. 2018 May;93(5):704-715
pubmed: 29634090
N Engl J Med. 2016 Jun 23;374(25):2419-29
pubmed: 27332902
Leuk Lymphoma. 2020 Dec;61(12):2931-2938
pubmed: 32842815
J Natl Compr Canc Netw. 2017 May;15(5):608-638
pubmed: 28476741
J Clin Oncol. 2016 Jun 10;34(17):2020-7
pubmed: 27069074
Hematol Oncol. 2021 Apr;39(2):185-195
pubmed: 33462822
J Clin Oncol. 2020 Dec 10;38(35):4149-4162
pubmed: 32946352
J Clin Oncol. 2018 Feb 10;36(5):454-462
pubmed: 29360414
Cancer Med. 2020 Sep;9(18):6565-6575
pubmed: 32710498
J Clin Oncol. 2007 Aug 20;25(24):3746-52
pubmed: 17646666
Lancet Oncol. 2019 Feb;20(2):202-215
pubmed: 30658935
N Engl J Med. 2018 Jan 25;378(4):331-344
pubmed: 29224502
Adv Hematol. 2011;2011:656013
pubmed: 21687649
J Clin Oncol. 2013 Feb 20;31(6):684-91
pubmed: 23182987
Cochrane Database Syst Rev. 2017 May 25;5:CD007941
pubmed: 28541603
Br J Haematol. 2013 Apr;161(1):76-86
pubmed: 23356491
J Natl Compr Canc Netw. 2018 Mar;16(3):245-254
pubmed: 29523663
J Clin Oncol. 2009 Sep 20;27(27):4548-54
pubmed: 19704068
Blood. 2019 Oct 10;134(15):1238-1246
pubmed: 31331918
Lancet Oncol. 2013 Sep;14(10):943-52
pubmed: 23948348
Haematologica. 2022 May 01;107(5):1086-1094
pubmed: 34162178
Lancet. 2015 Apr 11;385(9976):1418-27
pubmed: 25539730
Am J Hematol. 2020 Sep;95(9):1030-1037
pubmed: 32419224
Br J Haematol. 2015 Jul;170(2):179-84
pubmed: 25891777
Ann Hematol. 2020 Feb;99(2):277-282
pubmed: 31872362
N Engl J Med. 1998 Nov 19;339(21):1506-14
pubmed: 9819449